Regulatory
The GLP-1 Shortage Is Over: What That Means for Compounding
The legal basis for broad compounding narrowed. Access now hinges on documented clinical need.
The FDA shortages of semaglutide and tirzepatide that opened the door to mass-marketed compounding have resolved — which narrows the legal basis for that compounding. This piece explains what changed and why access now hinges more on documented clinical need.
How the shortage enabled broad compounding
Federal law restricts compounding of a drug that is "essentially a copy" of an available FDA-approved product — but that restriction eases when the approved drug is in shortage. When semaglutide and tirzepatide were on FDA's shortage list, compounders could supply versions to meet demand the manufacturers couldn't. That shortage window is what allowed the wave of telehealth compounded-GLP-1 programs to scale.
What resolution changes
With the shortages resolved and the products removed from FDA's shortage list, the broad legal basis for mass-marketed compounding of essentially-copies narrows substantially. Compounding doesn't become impossible — there remain lawful bases, such as a documented clinical need for a formulation the approved product doesn't offer (for example, a different dose or the removal of an ingredient a patient can't tolerate). But "we can compound this because it's in shortage" stops being the blanket justification, and access shifts toward individualized, clinically-justified compounding.
Why this matters to a consumer
Practically, this means the landscape is changing under providers' feet, and a program that relied on the shortage rationale may need to change its basis or its offering. It also raises the premium on providers that operate on a defensible, individualized-need basis rather than mass-marketing essentially-copies. As the manufacturer cash-pay prices for the approved products have also come down, the calculus of choosing compounded-over-approved shifts too.
What to watch
| Basis | During shortage | After resolution |
|---|---|---|
| "Essentially a copy" (mass-marketed) | Permitted while in shortage | Narrows substantially |
| Individualized clinical need | Available | Remains available |
| Legal footing | Broad | Shifts to documented need |
Regulatory and enforcement developments in this area are active and can change quickly. Treat any specific claim about what's currently permitted as time-sensitive, and confirm current status rather than relying on a cached description. This site tracks the regulatory framing but is not legal advice, and the specifics of what a given provider may lawfully offer are evolving.
Primary sources
This article's regulatory and safety statements draw on the following primary sources from the U.S. Food and Drug Administration:
- FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA — FD&C Act Provisions that Apply to Human Drug Compounding (503A vs 503B)
Frequently asked questions
Can compounded GLP-1s still be sold now that the shortage is over?
Compounding isn't banned, but the broad "it's in shortage" justification for mass-marketed essentially-copies narrows once the products leave FDA's shortage list. Lawful compounding on an individualized, clinically-justified basis can continue. The landscape is shifting, and specifics are time-sensitive — confirm current status rather than assuming.
Why does the shortage status matter legally?
Federal law restricts compounding drugs that are essentially copies of available approved products, and that restriction eases during a shortage. The shortage window is what enabled broad compounding; its resolution removes that blanket basis, shifting toward individualized clinical justification. It's a change in the legal footing, not an outright prohibition.
Will my provider still be available?
It depends on the basis your provider operates on. Programs that relied on the shortage rationale may need to adjust, while those operating on documented individualized need have firmer footing. Because the situation is evolving, confirm current availability directly rather than relying on older information.
Evidence status. Pricing figures are provider-reported or independently calculated as of 2026-07-20, not checkout-verified. Compounded medications are not FDA approved. This article is consumer education, not medical advice. See the methodology for how figures are gated and the public evidence ledger for per-figure sources. Found an error? Use the corrections route.